Nanostics is a clinical-stage precision health company developing novel and minimally invasive predictive risk stratification models to bring clarity to healthcare decisions.

Revolutionizing prostate cancer screening with ClarityDX Prostate

ClarityDX Prostate uses clinical and blood-based biomarkers to help quantify a patient’s risk of having aggressive prostate cancer helping patients and their healthcare providers make more informed healthcare decisions.

Dr. John Lewis

Dr. John Lewis

CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta

After over a decade of collaboration and innovation, powered by the generosity of so many, Nanostics had developed ClarityDX Prostate, a breakthrough that substantially enhances the prediction of aggressive prostate cancer and reduces the number of prostate biopsies, which are invasive, uncomfortable and carry some risk.

Recent News

Our success is possible thanks to the support of our many Canadian and international collaborators, funders, and partners.

Go to Top